Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ariflo COPD Long-Term Efficacy Studies Should Use Active Controls – Cmte.

Executive Summary

GlaxoSmithKline's long-term efficacy studies for Ariflo in chronic obstructive pulmonary disease should be designed as non-inferiority trials with active controls, members of FDA's Pulmonary-Allergy Drugs Advisory Committee suggested Sept. 5

You may also be interested in...



Quarterly Call Round-Up: Pfizer, GSK, Lilly Updates

Pfizer sees more savings from Pharmacia: Pfizer is now projecting "at least" $1 bil. in synergies from the Pharmacia acquisition in 2003, indicating that it expects to exceed its original target of $1 bil. in first-year savings...

Quarterly Call Round-Up: Pfizer, GSK, Lilly Updates

Pfizer sees more savings from Pharmacia: Pfizer is now projecting "at least" $1 bil. in synergies from the Pharmacia acquisition in 2003, indicating that it expects to exceed its original target of $1 bil. in first-year savings...

October User Fee Lineup Includes 7 NMEs; Many Expect “Approvable” Action

FDA enters the fourth quarter with at least 28 pending applications with October user fee deadlines, including seven new molecular entities and one new biologic

UsernamePublicRestriction

Register

PS042448

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel